Cite
Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma
MLA
Xiwen Tong, et al. “Real-World Experience with Selinexor-Containing Chemotherapy-Free or Low-Dose Chemotherapy Regimens for Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myeloid Sarcoma.” Frontiers in Pharmacology, vol. 14, Aug. 2023. EBSCOhost, https://doi.org/10.3389/fphar.2023.1217701.
APA
Xiwen Tong, Jie Jin, Bin Xu, Shuai Su, Li Li, Mengyuan Li, Yizhou Peng, Xia Mao, Wei Huang, & Donghua Zhang. (2023). Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1217701
Chicago
Xiwen Tong, Jie Jin, Bin Xu, Shuai Su, Li Li, Mengyuan Li, Yizhou Peng, Xia Mao, Wei Huang, and Donghua Zhang. 2023. “Real-World Experience with Selinexor-Containing Chemotherapy-Free or Low-Dose Chemotherapy Regimens for Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myeloid Sarcoma.” Frontiers in Pharmacology 14 (August). doi:10.3389/fphar.2023.1217701.